Osimertinib in Advanced Non–Small-Cell Lung Cancer

EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj

• #science_technology
• #take
• #nejm
• #nejm_quick_take
• #quick